FR2467602A1 - Procede pour la purification d'interferon et interferon ainsi obtenu - Google Patents
Procede pour la purification d'interferon et interferon ainsi obtenu Download PDFInfo
- Publication number
- FR2467602A1 FR2467602A1 FR8022617A FR8022617A FR2467602A1 FR 2467602 A1 FR2467602 A1 FR 2467602A1 FR 8022617 A FR8022617 A FR 8022617A FR 8022617 A FR8022617 A FR 8022617A FR 2467602 A1 FR2467602 A1 FR 2467602A1
- Authority
- FR
- France
- Prior art keywords
- interferon
- solution
- stage
- elution
- zinc chelate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000014150 Interferons Human genes 0.000 title claims abstract description 98
- 108010050904 Interferons Proteins 0.000 title claims abstract description 98
- 229940079322 interferon Drugs 0.000 title claims abstract description 97
- 238000000034 method Methods 0.000 title claims abstract description 56
- 230000008569 process Effects 0.000 title claims abstract description 37
- 239000000243 solution Substances 0.000 claims abstract description 79
- 239000011324 bead Substances 0.000 claims abstract description 44
- 239000011701 zinc Substances 0.000 claims abstract description 30
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 30
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 29
- 239000013522 chelant Substances 0.000 claims abstract description 28
- 238000000746 purification Methods 0.000 claims abstract description 25
- 241000282414 Homo sapiens Species 0.000 claims abstract description 22
- 238000004587 chromatography analysis Methods 0.000 claims abstract description 11
- 239000005373 porous glass Substances 0.000 claims abstract description 10
- 239000007864 aqueous solution Substances 0.000 claims abstract description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 27
- 238000010828 elution Methods 0.000 claims description 22
- 239000011521 glass Substances 0.000 claims description 19
- 239000007853 buffer solution Substances 0.000 claims description 16
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 14
- 239000002953 phosphate buffered saline Substances 0.000 claims description 14
- 239000011780 sodium chloride Substances 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 230000007935 neutral effect Effects 0.000 claims description 11
- 239000003463 adsorbent Substances 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 7
- 230000002378 acidificating effect Effects 0.000 claims description 7
- 238000001179 sorption measurement Methods 0.000 claims description 6
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 5
- 210000002950 fibroblast Anatomy 0.000 claims description 5
- 239000001632 sodium acetate Substances 0.000 claims description 5
- 235000017281 sodium acetate Nutrition 0.000 claims description 5
- 239000004593 Epoxy Substances 0.000 claims description 4
- 229920002684 Sepharose Polymers 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000007973 glycine-HCl buffer Substances 0.000 claims 1
- 102000003996 Interferon-beta Human genes 0.000 abstract description 10
- 108090000467 Interferon-beta Proteins 0.000 abstract description 10
- 230000000694 effects Effects 0.000 description 32
- 102000004169 proteins and genes Human genes 0.000 description 27
- 108090000623 proteins and genes Proteins 0.000 description 27
- 239000000047 product Substances 0.000 description 18
- 238000005406 washing Methods 0.000 description 15
- 238000011084 recovery Methods 0.000 description 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 11
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 9
- 239000007788 liquid Substances 0.000 description 6
- 239000007974 sodium acetate buffer Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 5
- 239000011592 zinc chloride Substances 0.000 description 5
- 235000005074 zinc chloride Nutrition 0.000 description 5
- 102000006992 Interferon-alpha Human genes 0.000 description 4
- 108010047761 Interferon-alpha Proteins 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 238000002731 protein assay Methods 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000008366 buffered solution Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000010908 decantation Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 235000011008 sodium phosphates Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical class [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002156 adsorbate Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000842 anti-protozoal effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000011281 clinical therapy Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- OPGYRRGJRBEUFK-UHFFFAOYSA-L disodium;diacetate Chemical compound [Na+].[Na+].CC([O-])=O.CC([O-])=O OPGYRRGJRBEUFK-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- -1 imino- Chemical class 0.000 description 1
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000002799 interferon inducing agent Substances 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000011173 large scale experimental method Methods 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000011049 pearl Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000005201 scrubbing Methods 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 238000011172 small scale experimental method Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- MVDZGCGHDDJODL-UHFFFAOYSA-L zinc;2-(carboxylatomethylamino)acetate Chemical compound [Zn+2].[O-]C(=O)CNCC([O-])=O MVDZGCGHDDJODL-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/565—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/811—Interferon
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL7907791A NL7907791A (nl) | 1979-10-23 | 1979-10-23 | Werkwijze voor het zuiveren van interferon. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2467602A1 true FR2467602A1 (fr) | 1981-04-30 |
| FR2467602B3 FR2467602B3 (OSRAM) | 1982-07-09 |
Family
ID=19834063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8022617A Granted FR2467602A1 (fr) | 1979-10-23 | 1980-10-22 | Procede pour la purification d'interferon et interferon ainsi obtenu |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US4359389A (OSRAM) |
| JP (1) | JPS5673028A (OSRAM) |
| CA (1) | CA1166959A (OSRAM) |
| CH (1) | CH647158A5 (OSRAM) |
| DE (1) | DE3039566A1 (OSRAM) |
| FR (1) | FR2467602A1 (OSRAM) |
| GB (1) | GB2061285B (OSRAM) |
| NL (1) | NL7907791A (OSRAM) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL58765A (en) * | 1979-11-21 | 1986-09-30 | Yeda Res & Dev | Process for the production of essentially pure messenger rna of human fibroblast interferon and process for the production of interferon beta |
| YU45104B (en) | 1980-04-03 | 1992-03-10 | Biogen Nv | Process for producing recombinant dnk molecule, capable of inducting polypeptide expression in an one-cell host |
| JPS5810056A (ja) * | 1981-07-10 | 1983-01-20 | 株式会社クラレ | 血液浄化装置 |
| JPH0751511B2 (ja) * | 1982-03-15 | 1995-06-05 | 味の素株式会社 | インターロイキン２を含有してなる癌治療剤 |
| JPS58201794A (ja) * | 1982-05-17 | 1983-11-24 | Toray Ind Inc | ヒトインターフェロンβの濃縮精製法 |
| US5643566A (en) * | 1982-09-23 | 1997-07-01 | Cetus Corporation | Formulation processes for lipophilic proteins |
| US4485017A (en) * | 1982-12-22 | 1984-11-27 | Cetus Corporation | Isolation of human interferon by immunosorbent and high performance liquid chromatography |
| IL67896A (en) * | 1983-02-13 | 1987-03-31 | Yeda Res & Dev | Two biologically active human gama interferon subtypes,purification thereof and pharmaceutical compositions containing them |
| CA1231306A (en) * | 1983-03-03 | 1988-01-12 | Erich Hochuli | Purification of interferon |
| US4723000A (en) * | 1983-07-05 | 1988-02-02 | Biospectrum, Inc. | Human interferon gamma and interleukin-2 |
| US4648975A (en) * | 1983-08-17 | 1987-03-10 | Pedro B. Macedo | Process of using improved silica-based chromatographic supports containing additives |
| US4499014A (en) * | 1984-02-07 | 1985-02-12 | Interferon Sciences, Inc. | Method for purifying gamma-interferon |
| US4770781A (en) * | 1986-03-03 | 1988-09-13 | Merck & Co., Inc. | Purification of human interleukin-1 species |
| US4732683A (en) * | 1986-12-02 | 1988-03-22 | Biospectrum, Inc. | Purification method for alpha interferon |
| US4846786A (en) * | 1987-04-30 | 1989-07-11 | Massachusetts Institute Of Technology | Bioreactor containing suspended, immobilized species |
| IT1222427B (it) * | 1987-07-31 | 1990-09-05 | Sclavo Spa | Procedimento per la purificazione di interferone |
| HU201100B (en) * | 1988-03-04 | 1990-09-28 | Egyt Gyogyszervegyeszeti Gyar | Process for large-scale production of high purity human leukocyte alpha interferon with reduced endotoxin content and with improved therapeutic effect |
| EP0551535A1 (en) * | 1992-01-13 | 1993-07-21 | SCLAVO S.p.A. | Process for the purification of recombinant human beta interferon, beta interferon thus purified, and pharmaceutical compositions which contain them |
| US6399296B1 (en) * | 1994-07-20 | 2002-06-04 | The General Hospital Corporation | Interaction trap systems for detecting protein interactions |
| CZ20032526A3 (cs) | 2001-02-27 | 2003-12-17 | Maxygen Aps | Nové molekuly podobné interferonu beta |
| AR034749A1 (es) * | 2001-07-09 | 2004-03-17 | Schering Ag | Formulaciones de interferon beta humano |
| KR100524872B1 (ko) * | 2003-12-04 | 2005-11-01 | 씨제이 주식회사 | 인터페론 베타의 정제방법 |
| KR100524871B1 (ko) * | 2003-12-04 | 2005-10-31 | 씨제이 주식회사 | 인터페론 베타의 정제방법 |
| DE102009032179A1 (de) | 2009-07-07 | 2011-01-13 | Biogenerix Ag | Verfahren zur Reinigung von Interferon beta |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1617401A1 (de) * | 1966-05-02 | 1972-02-17 | Centre Nat Rech Scient | Verfahren zur Herstellung von Interferon-Praeparaten |
| US4070284A (en) * | 1973-08-20 | 1978-01-24 | Hitachi, Ltd. | Liquid chromatography and apparatus for the same |
| NL7605805A (nl) * | 1976-05-28 | 1977-11-30 | Stichting Rega V Z W | Werkwijze voor het zuiveren van interferon. |
| DE2961658D1 (en) * | 1978-05-17 | 1982-02-18 | Thomae Gmbh Dr K | Process for preparing human interferon |
-
1979
- 1979-10-23 NL NL7907791A patent/NL7907791A/nl not_active Application Discontinuation
-
1980
- 1980-10-13 GB GB8032954A patent/GB2061285B/en not_active Expired
- 1980-10-17 US US06/198,223 patent/US4359389A/en not_active Expired - Lifetime
- 1980-10-20 DE DE19803039566 patent/DE3039566A1/de not_active Withdrawn
- 1980-10-20 CH CH7806/80A patent/CH647158A5/de not_active IP Right Cessation
- 1980-10-22 FR FR8022617A patent/FR2467602A1/fr active Granted
- 1980-10-23 JP JP14926280A patent/JPS5673028A/ja active Pending
- 1980-10-23 CA CA000363070A patent/CA1166959A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| CH647158A5 (de) | 1985-01-15 |
| US4359389A (en) | 1982-11-16 |
| JPS5673028A (en) | 1981-06-17 |
| GB2061285B (en) | 1983-03-30 |
| CA1166959A (en) | 1984-05-08 |
| GB2061285A (en) | 1981-05-13 |
| DE3039566A1 (de) | 1981-05-21 |
| NL7907791A (nl) | 1981-04-27 |
| FR2467602B3 (OSRAM) | 1982-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR2467602A1 (fr) | Procede pour la purification d'interferon et interferon ainsi obtenu | |
| CA1340742C (fr) | Procede de seperation par voie chromatographique de proteins du plasma, concentres de proteins obtenus, notamment de facteur viii, de fibrinogene, de facteur von willebrand et de fibronectine | |
| Swingle et al. | Tricalcium phosphate as an adsorbent in the chromatography of proteins | |
| CA2446704C (fr) | Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique | |
| JP4519646B2 (ja) | プレプロインスリンの精製方法 | |
| JPH06107561A (ja) | 静脈内相容性免疫グロブリン− ｇ− 製剤の製造方法 | |
| JP3438735B2 (ja) | 上清ｉｖ、特にｉｖ−４またはコーンフラクションｖまたはそれと類似の上清または画分からヒトアルブミンを単離する方法 | |
| US4168261A (en) | Method for the purification of interferon using porous glass beads | |
| EP4108673A1 (en) | Non-protein a purification method for adalimumab | |
| JPH0533239B2 (OSRAM) | ||
| EP0179006B1 (fr) | Procédé d'obtention du complexe FVIII/vWF à usage thérapeutique et produits en résultant | |
| JPS58201794A (ja) | ヒトインターフェロンβの濃縮精製法 | |
| JPS5832591B2 (ja) | ウロキナ−ゼの精製法 | |
| MC1499A1 (fr) | Interferon immun humain homogene et procede pour sa preparation | |
| CA1295985C (fr) | Procede pour la separation et la purification des antigenes proteiques des bacteries du genre bordetella | |
| CN115677848A (zh) | 一种制备高纯度高稳定性蛋白质的方法 | |
| CN113426423B (zh) | 用于血液体外循环去除ldl的吸附剂及其制备方法和灌流器 | |
| EP0242301B1 (fr) | Procédé de purification d'antigènes protéiques de bactéries appartenant au genre Bordetella, en vue de l'obtention d'un vaccin acellulaire | |
| RU2126690C1 (ru) | Способ очистки инсулина-сырца, получаемого из поджелудочной железы свиней | |
| CN1120365C (zh) | 一种新的亲和介质和用该介质纯化白蛋白的方法 | |
| JPS585191A (ja) | カリクレインの精製法 | |
| US6372510B1 (en) | Method for removing unconventional transmissible agents from a protein solution | |
| Grellet et al. | An associated process for the purification of immuno globulin g, catalase, superoxide dismutase and albumin from haemolysed human placenta blood | |
| CN116410295A (zh) | 一种大肠杆菌表达物的纯化方法 | |
| JPS628414B2 (OSRAM) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |